Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...

Rezera, formerly known as NodThera until a rebrand earlier this year, has announced the terms of its planned Nasdaq IPO, ...

For years, success in kidney disease has largely been measured by how much its progression could be slowed. Newer treatments ...

Moderna's mRNA-1469 and ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, ...

Netherlands-based argenx has published positive topline results from its ADAPT SERON trial of its market-leading drug for generalised myasthenia gravis (gMG) Vyvgart (efgartigimod). Significantly, the ...

Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

T-Therapeutics and Alethio Therapeutics – have raised $133 million and $90 million, respectively, in an impressive pair of ...

The one-year-old start-up is the latest to receive financial backing from the UK government's £500 million Sovereign AI (SovAI) fund, and is working on a platform that "could make the design of new ...

In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.

Businesses are finding that AI is a great leveller. Organisations with mature digital infrastructures can use AI to unlock ...